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Randomized controlled trialAbstract Introduction: The beneﬁcial effects of tiotropium bromide, a long acting anticholinergic
bronchodilator, in the management of chronic obstructive pulmonary disease have been shown in
previous studies. The present study aimed to compare the efﬁcacy and safety of generic (Tiova)
and brand-name (Spiriva) tiotropium preparations in patients with COPD. Methods and materi-
als: In this randomized double-blind parallel-group trial, 79 patients with documented COPD were
assigned to Tiova or Spiriva for a period of 4 weeks. Assessment of pulmonary function (using
spirometry), quality-of-life (using St. George respiratory Questionnaire [SGRQ]) and severity of
148 Y. Panahi et al.respiratory symptoms (using breathlessness, cough and sputum scale [BCSS]) was performed at
baseline and at the end of treatment period. Results: There were signiﬁcant increases in FEV1
and reductions in FVC by the end of study in both Tiova and Spiriva groups. FEV1/FVC ratio
did not change signiﬁcantly neither in the Tiova nor in Spiriva group. Overall SGRQ score as
well as subscale scores of symptoms, activity and impacts were improved by both drugs. In the
BCSS scale, the frequency and severity of three main symptoms (dyspnea, cough and sputum)
was decreased by both drugs. Baseline as well as post-treatment values of spirometric parameters,
SGRQ and BCSS scores was comparable between the groups, apart from a lower post-treatment
frequency of cough and sputum in the Spiriva versus Tiova group. There was no report of
adverse events in either of the study groups. Conclusion: The ﬁndings of this comparative trial
showed equivalent efﬁcacy and safety of Spiriva and Tiova in lessening the symptoms as well
as improving the quality of life in patients with COPD. This ﬁnding has an important translational
value given the signiﬁcantly lower costs of generic versus brand-name products.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is a patho-
logic state which is characterized by chronic, progressive and
irreversible airﬂow obstruction, leading to impaired pulmon-
ary function. Smoking is the major risk factor for COPD
(Currie, 2010). According to WHO estimates, 65 million
people had COPD in 2005 and more than 3 million people died
because of COPD in this year, amounting to 5% of all deaths
globally. COPD was the 5th cause of death in 2002 all over the
world and currently it is the third cause of death, preceded by
ischemic heart disease and stroke. Moreover, 90% COPD-
associated deaths occur in low- and middle-income countries.
In Iran, COPD was among the four main non-communicable
diseases which led to death in 2012 (Semba et al., 2014).
COPD is a chronic state that is accompanied by symptoms
such as productive coughs and dyspnea. By progression of
COPD, exacerbations become more frequent and are often
triggered by respiratory bacterial infections, predisposing to
several life-threatening conditions such as left ventricular
failure, cardiac arrhythmia, pneumothorax, pneumonia and
pulmonary thromboembolism (Longo et al., 2011). Although
complete control of COPD is difﬁcult, pharmacotherapy can
alleviate the symptoms, slow the disease progression, reduce
the frequency and severity of exacerbations and also prevent
mortality. Bronchodilators and inhaled corticosteroids are
routinely administered medications for COPD management
(Hanania and Sharafkhaneh, 2010). Bronchodilators have also
been shown to be helpful in patients with increased airway
hypersensitivity. Combination of a b2-agonist (e.g. salbutamol)
and an anticholinergic (e.g. ipratropium bromide) has been
found to be more effective than any of the other bronchodila-
tors used alone (Balali-Mood and Hefazi, 2005).
Anticholinergic bronchodilators are widely used as stan-
dard treatments of COPD. Anticholinergics are indicated in
all stages of COPD and are available in two forms: short-
acting (ipratropium bromide) and long-acting (tiotropium
bromide) (Vestbo et al., 2013). These bronchodilators block
muscarinic receptors, resulting in relaxation and dilatation of
airways and attenuation of mucus secretion (Kato et al.,
2006). Tiotropium bromide is preferred over ipratropium
bromide because of its speciﬁc inhibition of M3 receptors
and longer duration of action (Vestbo et al., 2013). Tiotropiumbromide is marketed under two trade names Spiriva
(manufactured by Boehringer-Ingelheim, Germany) and
Tiova (manufactured by Cipla, India). Tiova is a generic
product that is less expensive than the brand-name product
(Spiriva) (Tan and de Haan, 2014). Hitherto, only Spiriva
has been available and prescribed in Iran.
The present study aimed to compare the efﬁcacy and safety
of brand and generic products of tiotropium bromide in
patients suffering from COPD.2. Material and methods
This study was designed as a randomized double-blind clinical
trial. Subjects were recruited from those referring to the
Respiratory Clinic of the Baqiyatallah Hospital (Tehran, Iran).
Inclusion criteria were documented history of COPD, age
between 30 and 60 years, absence of spirometry contraindica-
tion, and a negative history of coagulopathy, prostate
hypertrophy and glaucoma. Subjects with a history of
hypersensitivity to tiotropium bromide, cigarette smoking,
occupational exposure to toxic chemicals, allergic rhinitis or
any other type of allergy, asthma, tuberculosis, lung cancer,
systemic diseases with pulmonary complications (e.g. heart
failure, renal dysfunction, hepatitis, cirrhosis and connective
tissue disorders), anemia or polycythemia, and acute respira-
tory infection were excluded from the study.2.1. Treatment
Eligible subjects were randomized to receive either Spiriva
(n= 33) or Tiova (n= 46). Patients were instructed to take
one capsule of either of the drugs daily at 12:00 a.m. Each
capsule contained 18 lg of tiotropium bromide dry powder.
Both study drugs were inhaled by the aid of appropriate
apparatus i.e. Revolizer (made by Cipla Ltd. For the use
of Tiova) and Handihaler (made by Boehringer-
Ingelheimmade Ltd. for the use of Spiriva). During the
study, all patients continued their standard COPD treatment
regimen including Seretide inhaler (containing Fluticasone
and Salmeterol; one puff every 12 h), and N-acetylcysteine
(600 mg every 12 h).
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Spirometric assessments were performed on a HI-801 Chest
M.I. Spirometer (Tokyo, Japan), calibrated according to the
manufacturer’s instructions. Pulmonary function was assessed
by measuring forced expiratory volume in the ﬁrst second
(FEV1), forced vital capacity (FVC), and FEV1/FVC ratio at
baseline and at the end of trial.
Breathlessness, cough and sputum scale (BCSS) was used to
assess the severity of three main symptoms of COPD that are
most likely affected by standard COPD treatment. BCSS is a
reliable and easy-to-use medical tool to explore the severity
of respiratory symptoms and efﬁcacy of treatment in clinical
trials of COPD. Each item in BCSS is answered on a 5-point
likert scale, representing the severity of symptoms (Leidy
et al., 2003).
Evaluation of quality of life was performed using
St. George’s Respiratory Questionnaire (SGRQ) at baseline
and at the end of treatment. After receiving instructions about
how to ﬁll the questionnaire, subjects were asked to answer
SGRQ in a calm place independently, in the presence of an
observer. SGRQ contains 76 items categorized in three sub-
scales: ‘‘Symptoms’’ which asks about respiratory symptoms,
their frequency and severity; ‘‘Activity’’ which asks about
activities that cause or are limited by dyspnea; and ‘‘Impacts’’
which asks about social functioning and psychosocial disor-
ders due to lung disease. The overall score ranges between 0
and 100, and higher scores indicate more severe impairment.
SGRQ has been reported to be a sensitive, repeatable and
numerical tool for evaluating a range of disorders affecting
quality of life in patients with airway diseases (Jones et al.,
1991).
The results of SGRQ and BCSS were analyzed by an inter-
nist or a lung subspecialist. The study protocol was approved
by the institutional Ethics Committee and written informed
consent was obtained from all participants.
2.3. Statistical analysis
Data were analyzed using SPSS software, version 16.0. Within-
group comparisons were made using paired samples t-test (for
normally distributed data) or Wilcoxon signed-ranks test (for
non-normally distributed data). Comparisons of baseline and
post-treatment values between the study groups was carried
out using independent samples t-test (for normally distributed
data) or Mann–Whitney U test (for non-normally distributed
data). Categorical variables were compared using McNemar’s
(within-group) or Fisher’s exact (between-group) test. ATable 1 Spirometric ﬁndings in the study groups at baseline and a
Tiova Spiri
Pre-treatment Post-treatment p-Value Pre-t
FEV1 77.00 ± 34.20 81.38 ± 32.15 0.048 64.0
FVC 208.41 ± 132.70 80.58 ± 24.24 <0.001 179.4
FEV1/FVC 95.66 ± 37.25 94.84 ± 31.52 0.671 98.5
Values are mean ± SD. FEV1: forced expiratory volume in 1 s; FVC: fo
a Comparison of pre-treatment values between the groups.
b Comparison of post-treatment values between the groups.two-sided p-value of <0.05 was considered as statistically
signiﬁcant.
3. Results
Out of the 79 eligible COPD patients (46 patients in the
Tiova and 33 patients in the Spiriva group) who were ini-
tially recruited to the trial, 71 completed the study (n= 38
and 24 in the Tiova and Spiriva group, respectively). The
reason for dropping from trial was not taking study medica-
tions due to personal reasons. Drop-out rate was not signiﬁ-
cantly different between the study groups (p> 0.05). The
groups were comparable regarding age (48.78 ± 16.89 yrs
and 46.69 ± 15.62 yrs in the Tiova and Spiriva group,
respectively), gender (% males = 92.7% and 80% in the
Tiova and Spiriva group, respectively) and BMI
(24.12 ± 6.12 kg/m2 and 24.38 ± 5.49 kg/m2 in the Tiova
and Spiriva group, respectively) (p> 0.05).
3.1. Spirometric ﬁndings
Spirometric ﬁndings in the study groups before and after the
treatment are shown in Table 2. There were signiﬁcant
increases in FEV1 by the end of study in both Tiova
(p= 0.048) and Spiriva (p= 0.027) groups. In contrast,
FVC values were signiﬁcantly decreased in both groups
(p< 0.001 and p< 0.05 in the Tiova and Spiriva group,
respectively). FEV1/FVC ratio did not change signiﬁcantly
neither in the Tiova nor Spiriva group (p> 0.05). The
impact of studied drugs on the spirometric parameters was
comparable since baseline as well as post-treatment values
for FEV1, FVC and FEV1/FVC was not signiﬁcantly different
between the groups (p > 0.05). Spirometric ﬁndings in the
Tiova and Spiriva group are shown in Table 1.
3.2. SGRQ
In this study, the impact of administered medications on the
quality of life was evaluated using SGRQ. Overall SGRQ score
was signiﬁcantly reduced after 4 weeks of treatment with either
Tiova (p= 0.002) or Spiriva (p< 0.01). Subscale analysis
revealed that both drugs improved activities (p < 0.001 in the
Tiova group and p< 0.01 in the Spiriva group) and
impacts (p= 0.002 in the Tiova group and p< 0.001 in
the Spiriva group) scores, whilst the symptoms subscale score
remained statistically unaltered in both groups (p> 0.05).
Between-group comparisons indicated that total as well as sub-
scale SGRQ scores did not signiﬁcantly differ between thefter treatment.
va p-Valuea p-Valueb
reatment Post-treatment p-Value
7 ± 28.32 84.61 ± 34.38 0.027 0.673 0.461
1 ± 87.67 94.36 ± 31.24 <0.05 0.09 0.09
6 ± 35.40 102.72 ± 41.39 0.572 0.07 0.08
rced vital capacity.
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(p> 0.05). The effects of studied medications on the quality
of life are summarized in Table 2.3.3. BCSS
The severity of respiratory symptoms was evaluated using
BCSS. The frequencies of cough, dyspnea, morning dyspnea
and sputum were signiﬁcantly reduced in both Tiova and
Spiriva groups by the end of trial (p < 0.05). The frequency
of none of the BCSS items (cough, dyspnea, morning dyspnea,Table 2 Comparison of quality of life indices between the study gr
Tiova
Pre-treatment Post-treatment p-Value
Physical functioning 55.73 ± 36.22 64.31 ± 30.44 0.001
Role limitation health 76.88 ± 41.37 79.17 ± 40.31 0.495
Role limitation emotion 78.70 ± 41.37 77.78 ± 42.16 0.160
Energy fatigue 48.74 ± 22.39 48.11 ± 23.43 0.285
Emotional well 50.34 ± 22.69 49.62 ± 22.77 0.180
Social functioning 83.33 ± 22.95 84.72 ± 21.36 0.257
Pain 93.13 ± 15.46 93.43 ± 14.78 0.180
General health 39.51 ± 12.64 42.86 ± 15.78 0.843
Symptom score 49.31 ± 21.67 46.26 ± 21.07 >0.999
Activity score 47.59 ± 33.97 32.39 ± 21.81 <0.001
Impact score 23.22 ± 23.27 9.02 ± 12.05 0.002
Total score 66.83 ± 189.58 20.40 ± 11.52 <0.01
Values are mean ± SD. SGRQ: St. George respiratory Questionnaire.
a Comparison of pre-treatment values between the groups.
b Comparison of post-treatment values between the groups.
Table 3 Comparison of BCSS indices between the study groups.
Parameter Frequency Tiova
Pre-treatment
(%)
Post-treatment
(%)
p-Val
Cough Seldom 41.5 44.7 0.36
Little 26.8 31.6
Average 2.4 13.2
High 22.0 2.6
Very high 7.3 7.9
Dyspnea Seldom 26.8 32.5 0.018
Little 29.5 35.0
Average 17.1 20.0
High 29.3 5.1
Very high 7.3 2.6
Morning dyspnea Seldom 48.8 48.7 0.015
Little 12.2 23.1
Average 12.2 20.5
High 19.5 5.1
Very high 7.3 2.6
Sputum No 19.5 26.3 0.046
Yes 80.5 73.7
Bloody sputum No 87.8 96.9 0.317
Yes 12.2 3.1
BCSS: breathlessness, cough and sputum scale.
a Comparison of pre-treatment values between the groups.
b Comparison of post-treatment values between the groups.sputum and hemoptysis) did signiﬁcantly differ between the
study groups at baseline (p> 0.05).However, a lower frequency
of cough (p= 0.028) and sputum (p= 0.003) was observed
with Spiriva compared with Tiova at the end of trial
(Table 3).
3.4. Adverse events
Throughout the trial, both drugs were well tolerated and there
was no report of typical anticholinergic side effects such as dry
mouth, urinary retention and constipation in either of the
groups.oups according to SGRQ.
Spiriva p-Valuea p-Valueb
Pre-treatment Post-treatment p-Value
63.23 ± 28.12 68.24 ± 31.24 0.001 0.228 0.461
74.14 ± 39.27 79.27 ± 38.41 0.362 0.921 0.09
74.29 ± 37.50 76.18 ± 38.26 0.128 0.783 0.08
49.84 ± 18.29 47.24 ± 31.13 0.147 0.897 0.214
48.24 ± 25.39 46.12 ± 23.17 0.241 0.245 0.841
74.26 ± 26.31 77.12 ± 19.26 0.358 0.138 0.822
84.42 ± 21.34 78.37 ± 17.18 0.112 0.085 0.812
36.41 ± 14.74 45.16 ± 18.21 0.163 0.167 0.217
44.17 ± 19.53 49.36 ± 21.71 0.712 0.158 0.114
43.19 ± 27.71 31.23 ± 18.60 <0.01 0.389 0.09
19.27 ± 13.17 7.69 ± 4.32 <0.001 0.115 0.148
87.83 ± 47.58 29.43 ± 19.62 <0.01 0.713 0.132
Spiriva p-Valuea p-Valueb
ue Pre-treatment
(%)
Post-treatment
(%)
p-Value
46.6 50.0 <0.05 0.568 0.028
30.0 36.6
3.3 3.3
13.3 6.6
6.6 3.3
33.3 43.3 <0.05 0.107 0.070
24.2 30.0
16.6 23.3
13.3 3.3
10.0 0
56.6 63.3 <0.05 0.681 0.167
10.0 20.0
13.3 10.0
13.3 3.3
6.6 3.3
24.2 46.6 <0.05 0.494 0.003
73.3 53.3
90.0 100 0.112 0.822 0.246
10.0 0
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In pharmaceutical industry, generics are comparable with
brand-name products in terms of safety and therapeutic efﬁ-
cacy, while they are signiﬁcantly cheaper (20–90%) (Dunne
et al., 2013; Keith et al., 1998). Because of cost-efﬁciency
and wider availability, the policy of prescription of generic
products instead of brand-name products has been accepted
in many countries including Iran (since 1980) (Nelson et al.,
2006; Zargarzadeh et al., 2007; Dupont and Heller, 2009).
However, before a generic product could be regarded as a sub-
stitute for the original drug, its efﬁcacy and safety are required
to be demonstrated by bioequivalence (non-inferiority) trials
(Heshmat et al., 2007; Aleyasin et al., 2012; Hadjibabaie
et al., 2013; Beiraghdar et al., 2012a,b). With respect to COPD,
the importance of developing generic drugs is more important,
given the high burden of mortality that occurs in low- and mid-
dle-income countries, where access to brand-name medications
may not be easy and affordable (Semba et al., 2014). Hence,
decreasing treatment-associated costs should be considered
as an important and determining factor in the pharmacother-
apy of COPD.
Tiotropium bromide is an inhaled long-acting anticholiner-
gic bronchodilator which beneﬁts patient with COPD includ-
ing those with chronic bronchitis or emphysema. Long-term
treatment with tiotropium bromide has been reported to
improve exercise tolerance, health-related quality of life, and
decrease dyspnea exacerbations and mortality (Tashkin
et al., 2008; Balali-Mood and Hefazi, 2005). An important
ﬁnding arising from the present study was the equivalent efﬁ-
cacy and safety of Tiova, as a generic drug, compared with
Spiriva, as a brand name product. In spirometry, both
Tiova and Spiriva improved FEV1 signiﬁcantly that is
consistent with a meta-analysis of 22 randomized controlled
trials on the efﬁcacy of tiotropium bromide in the treatment
of COPD (Karner et al., 2012). FEV1 is a widely used measure
for the assessment of the degree of airﬂow limitation, and its
increase was comparable between Spiriva and Tiova. Our
spirometric evaluations were complimented by assessment of
quality of life and the frequency of symptoms. SGRQ is a
reliable measure of health status in patients with COPD, and
reﬂects the frequency of symptoms and the inﬂuence of breath-
lessness on daily activities as well as social functioning and
psychological wellness. Our ﬁndings indicated that all three
subscales of SGRQ (symptoms, activity and impacts) were
signiﬁcantly improved by both drugs, and that these improve-
ments were equivalent between both groups. These ﬁndings
are compliant with the results of two meta-analyses, including
a Cochrane review, on the quality of life (assessed using
SGRQ) in subjects receiving tiotropium bromide versus pla-
cebo. These studies indicated that tiotropium bromide
improves quality of life in COPD patients (Karner et al.,
2012; Yohannes et al., 2011). The positive effects of tiotropium
bromide on quality of life were further conﬁrmed by the results
of BCSS, in which both studied drugs were found to reduce the
severity of main COPD symptoms i.e. breathlessness, cough
and sputum.
In summary, our comparative trial, being the ﬁrst of its
kind, showed comparable efﬁcacy and safety of Spiriva
and Tiova in lessening the symptoms as well as improving
the quality of life in patients suffering from COPD. Thisﬁnding has an important translational value for patients with
COPD because of the lower cost of Tiova versus Spiriva
(Spiriva costs about three times as much as Tiova), and
the long-term nature of pharmacotherapy in COPD. In light
of the present ﬁndings, Tiova can be suggested as an effective
and safe replacement for Spiriva. However, since duration of
follow-up in this pilot trial was relatively short, future
large-scale studies are still required to compare the safety
proﬁle and quality of life-improving effects of Tiova versus
Spiriva over longer-term periods.
Acknowledgments
This study was ﬁnancially supported by a grant from Clinical
Trials Research center, Tehran, Iran.
References
Aleyasin, A., Hanaﬁ, S., Saffarieh, E., Torkamandi, H., Allahyari, S.,
Sadeghi, F., Javadi, M., 2012. Efﬁcacy of generic granisetron vs
Kytril for PONV in major gynecological operations: a randomized,
double-blind clinical trial. Iranian J. Pharm. Res.: IJPR 11, 1059.
Balali-Mood, M., Hefazi, M., 2005. The pharmacology, toxicology,
and medical treatment of sulphur mustard poisoning. Fundam.
Clin. Pharmacol. 19, 297–315.
Beiraghdar, F., Panahi, Y., Einollahi, B., Nemati, E., Ghadiani, M.H.,
Sahebkar, A., Maghsoudi, N., Marzony, E.T., 2012a. Investigation
of the efﬁcacy of a biogeneric recombinant human erythropoietin
alfa in the management of renal anemia in patients on hemodial-
ysis: a multi-center clinical trial. Clin. Lab. 58, 737–745.
Beiraghdar, F., Panahi, Y., Einollahi, B., Torkaman, M., Moham-
madi, R., Marzony, E.T., Sahebkar, A., 2012b. Investigation of the
efﬁcacy of a biogeneric recombinant human erythropoietin alfa in
the correction of post-transplantation anemia: a randomized
comparative trial with Eprex. Clin. Lab. 58, 1179–1185.
Currie, G.P., 2010. ABC of COPD. Wiley.
Dunne, S., Shannon, B., Dunne, C., Cullen, W., 2013. A review of the
differences and similarities between generic drugs and their
originator counterparts, including economic beneﬁts associated
with usage of generic medicines, using Ireland as a case study. BMC
Pharmacol. Toxicol. 14, 1.
Dupont, A.G., Heller, F., 2009. Generics and cost-effective prescribing
in Belgium: does bioequivalence always translate in therapeutic
equivalence? Acta Clin. Belg. 64, 406–414.
Hadjibabaie, M., Khoee, S.H., Nematipoor, E., Gholami, K.,
Fatahian, A., Jahangard, Z., 2013. Comparison of efﬁcacy and
tolerability of different brands of amlodipine in patients with mild
to moderate hypertension. J. Pharm. Care 1, 41–44.
Hanania, N.A., Sharafkhaneh, A., 2010. COPD: A Guide to Diagnosis
and Clinical Management. Humana Press.
Heshmat, R., Taheri, E., Larijani, B., 2007. Comparison of a generic
and a brand metformin products in type II diabetes: a double blind
randomized clinical trial study. DARU J. Pharm. Sci. 15, 113–117.
Jones, P.W., Quirk, F., Baveystock, C., 1991. The St George’s
respiratory questionnaire. Respir. Med. 85, 25–31.
Karner, C., Chong, J., Poole, P., 2012. Tiotropium versus placebo for
chronic obstructive pulmonary disease. Cochrane Database Syst.
Rev., 7
Kato, M., Komamura, K., Kitakaze, M., 2006. Tiotropium, a novel
muscarinic M3 receptor antagonist, improved symptoms of chronic
obstructive pulmonary disease complicated by chronic heart
failure. Circulation J.: Ofﬁcial J. Jpn. Circulation Soc. 70, 1658–
1660.
Keith, L.G., Oleszczuk, J.J., Stika, C.S., Stine, S., 1998. Generics:
what’s in a name? Int. J. Fertil Womens Med. 43, 139–149.
152 Y. Panahi et al.Leidy, N.K., Rennard, S.I., Schmier, J., Jones, M.K.C., Goldman, M.,
2003. The breathlessness, cough, and sputum scale the development
of empirically based guidelines for interpretation. CHEST J. 124,
2182–2191.
Longo, D.L., Fauci, A.S., Kasper, D.L., Hauser, S.L., Jameson, J.L.,
Loscalzo, J., 2011. Harrison’s Principles of Internal Medicine, 18th
ed. McGraw-Hill Education.
Nelson, S., Slordal, L., Spigset, O., 2006. Generic drugs instead of
brand drugs prescriptions–long overdue. Tidsskr. Nor. Laegeforen
126, 441–443.
Semba, R.D., Ferrucci, L., Bartali, B., Urpı´-Sarda, M., Zamora-Ros,
R., Sun, K., Cherubini, A., Bandinelli, S., Andres-Lacueva, C.,
2014. Resveratrol levels and all-cause mortality in older commu-
nity-dwelling adults. JAMA Internal Med. 174, 1077–1084.
Tan, S.M., de Haan, J.B., 2014. Combating oxidative stress in diabetic
complications with Nrf2 activators: how much is too much? Redox
Rep. 19, 107–117.Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge,
S., Decramer, M., 2008. A 4-year trial of tiotropium in
chronic obstructive pulmonary disease. N. Engl. J. Med. 359,
1543–1554.
Vestbo, J., Hurd, S.S., Agusti, A.G., Jones, P.W., Vogelmeier, C.,
Anzueto, A., Barnes, P.J., Fabbri, L.M., Martinez, F.J.,
Nishimura, M., 2013. Global strategy for the diagnosis, manage-
ment, and prevention of chronic obstructive pulmonary disease:
GOLD executive summary. Am. J. Respir. Crit. Care Med. 187,
347–365.
Yohannes, A.M., Willgoss, T.G., Vestbo, J., 2011. Tiotropium for
treatment of stable COPD: a meta-analysis of clinically relevant
outcomes. Respir. Care 56, 477–487.
Zargarzadeh, A.H., Emami, M.H., Hosseini, F., 2007. Drug-related
hospital admissions in a generic pharmaceutical system. Clin. Exp.
Pharmacol. Physiol. 34, 494–498.
